A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
Status:
Recruiting
Trial end date:
2024-11-27
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to measure the effect of different daily doses of
AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with
dyslipidemia. The effect of AZD0780 versus placebo on other lipid parameters and inflammatory
markers is also investigated. The concentration of AZD0780 in blood at specific timepoints is
measured, and the safety and tolerability of AZD0780 will be evaluated. There is a follow-up
after end of treatment, but expanded access is not available. The primary hypothesis is that
at least one of the investigated doses of AZD0780 is superior to placebo in lowering LDL-C
level, in percent change from baseline up to week 12.